AXQ Capital LP Takes Position in Catalyst Pharmaceuticals, Inc. $CPRX

AXQ Capital LP acquired a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the fourth quarter, HoldingsChannel reports. The firm acquired 17,372 shares of the biopharmaceutical company’s stock, valued at approximately $405,000.

Other institutional investors have also modified their holdings of the company. One Capital Management LLC increased its position in Catalyst Pharmaceuticals by 61.1% during the fourth quarter. One Capital Management LLC now owns 74,973 shares of the biopharmaceutical company’s stock worth $1,750,000 after purchasing an additional 28,433 shares during the last quarter. Future Fund LLC increased its position in Catalyst Pharmaceuticals by 61.1% during the fourth quarter. Future Fund LLC now owns 74,973 shares of the biopharmaceutical company’s stock worth $1,750,000 after purchasing an additional 28,433 shares during the last quarter. Intech Investment Management LLC increased its position in Catalyst Pharmaceuticals by 27.6% during the fourth quarter. Intech Investment Management LLC now owns 69,447 shares of the biopharmaceutical company’s stock worth $1,621,000 after purchasing an additional 15,034 shares during the last quarter. Geode Capital Management LLC grew its stake in Catalyst Pharmaceuticals by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 2,900,337 shares of the biopharmaceutical company’s stock worth $67,704,000 after buying an additional 10,017 shares during the period. Finally, Steel Grove Capital Advisors LLC purchased a new stake in Catalyst Pharmaceuticals during the fourth quarter worth approximately $206,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

CPRX stock opened at $31.29 on Friday. The stock has a market cap of $3.83 billion, a P/E ratio of 17.98, a P/E/G ratio of 0.95 and a beta of 0.74. The firm has a 50 day simple moving average of $28.29 and a 200 day simple moving average of $25.29. Catalyst Pharmaceuticals, Inc. has a 52 week low of $19.05 and a 52 week high of $32.56.

Analyst Upgrades and Downgrades

Several research firms have issued reports on CPRX. Truist Financial upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, March 25th. Oppenheimer lowered shares of Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, May 7th. Robert W. Baird lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. Zacks Research cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 18th. Finally, Weiss Ratings upgraded Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).